Solventum Earnings Reports

Solventum delivered a solid quarter with total sales reaching $2.074 billion, marking a 1.9% increase year-over-year. GAAP diluted EPS stood at $0.17, while adjusted EPS reached $1.41. The company generated $219 million in operating cash flow and achieved $92 million in free cash flow. Organic sales growth was led by MedSurg and Dental Solutions segments.

Solventum reported a 0.4% increase in sales to $2.082 billion for Q3 2024, with organic sales increasing by 0.3%. GAAP EPS was $0.70, and adjusted EPS was $1.64. The company generated $169 million in cash from operations and $76 million in free cash flow. Solventum raised its full-year 2024 organic sales growth, adjusted EPS, and free cash flow guidance.

Solventum reported its Q2 2024 financial results, highlighting a slight increase in reported sales and organic sales growth. The company's GAAP EPS was $0.51, while adjusted EPS reached $1.56. Solventum generated $355 million in cash from operations and $297 million in free cash flow. The company also raised its full-year 2024 organic sales growth and adjusted EPS guidance.

Solventum reported its first quarter 2024 financial results, marking its first quarter as an independent company after the spin-off from 3M on April 1, 2024. Sales increased by 0.2% to $2.016 billion, with organic sales up by 0.9%. The company reported GAAP EPS of $1.37 and adjusted EPS of $2.08. Solventum generated $442 million in cash from operations and $340 million in free cash flow. The company reaffirms its full-year 2024 guidance.